News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Today's investor conference call with AVRW management was outstandingly positive in all respects. Every important point was covered well and in detail. All real investors in AVRW should take the time to review this presentation when the replay is made available on the company website shortly. Management also issued and open invitation for all interested parties to call them directly with any specific questions now. Additionally, they stated there will be new announcements coming up regarding all their plans and new programs for 2025. I was very pleased with everything I heard on the AVRW conference call today. Well done.
Looking forward to the conference call. Good to hear from management now that this debt issue has been negotiated.
Note that AVRW management will be hosting a public conference call on Wednesday this week as detailed below:
--------------------------------------------------------------------
Overall, Avenir Wellness Solutions has never been in a better position to capitalize on the high intrinsic value of our Nutri-Strip products as well as our unique and proprietary skin care formulations. With 17 patents under our control, the highly positive reviews Seratopical Revolution DNA Complex is receiving, and more new products in development, 2025 is setting up to be a growth year for the Company. We look forward to keeping our shareholders informed of our progress, developments and milestones as we move forward.
Company Management will be hosting an investor webcast/call to discuss the settlement agreement and provide an update on the Company on Wednesday, December 18, 2024 at 1:00pm PST / 4:00pm EST. Questions may be submitted prior to the webcast by emailing them to investor@avenirwellness.com. To participate in the webcast, please join us at:
https://us06web.zoom.us/j/83688826398?pwd=NzGBQ928B7m34yGgLPBPLI77BY4lGF.1
Meeting ID: 836 8882 6398
Passcode: 797030
One tap mobile
+16694449171,,83688826398#,,,,*797030# US
+13462487799,,83688826398#,,,,*797030# US (Houston)
$AVRW News: Avenir Wellness Solutions Announces Global Settlement with Ionic Ventures, Eliminating Convertible Debt
SHERMAN OAKS, CA / ACCESSWIRE / December 16, 2024 / Avenir Wellness Solutions, Inc. ("Avenir" or the "Company") (OTCQB:AVRW), a proprietary broad platform technology beauty and wellness company, today announced that it has reached a global settlement with its current debt holder Ionic Ventures LLC ("Ionic") to resolve all disputes between the parties.
In connection with the settlement, a portion of the outstanding convertible notes with an aggregate carrying value of $8.7 million as of September 30, 2024 will be converted into approximately 8.3 million shares of the Company's common stock at a value of approximately $233 thousand, subject to a leak-out agreement. The remaining amount of convertible notes will be extinguished in exchange for a new 10%/11% two-year note with a principal amount of $2.85 million to be issued to Ionic, inclusive of legal fees Ionic incurred in defending against the lawsuit filed by Avenir in the dispute. The new note will require payment equal to at least 50% of the net proceeds the Company receives if it completes a qualified financing, asset sale or M&A transactions up to the accreted amount of the note, but not later than the two-year anniversary of the issuance of the note. As a result of the extinguishment, the Company is expected to recognize a one-time gain of approximately $5.0 million during the fourth quarter of 2024.
The Company also has withdrawn its lawsuit filed against Ionic in the State of New York in connection with the convertible notes originally issued in 2020. As part of the settlement, Avenir acknowledged that Ionic at all times conducted itself in compliance with the 2020 transaction documents, and the settlement agreement reflects that Ionic admitted to no wrongful conduct in connection with the underlying transaction. For further information on the settlement, please refer to the recently filed Form 8-K.
"Despite building a plant-based wellness and beauty business with very high gross margins the last two full fiscal years, Avenir's total market cap has been severely depressed with the value of the entire company recently totaling less than half of last year's sales. After discussions with our financial advisors, Board of Directors and largest shareholders, we confirmed it is universally believed that the significant outstanding convertible debt is the primary reason why there is a disconnect between Company's market value with its underlying business. Our shareholders were clear that our top priority should be elimination of the convertible debt and the settlement of litigation commenced against Ionic. As such, we have been in active negotiations with Ionic for the past few months and were able to come to terms that we believe are extremely beneficial to the Company and our shareholders," commented Nancy Duitch, Chief Executive Officer of Avenir.
Duitch added, "We are thrilled with this transaction that, together with a bridge financing we are in the process of completing, significantly strengthens our balance sheet and eliminates the overhang our shareholders have cited as the significant obstacle preventing them from increasing their ownership of our stock."
Brendan O'Neil, Ionic's Manager, stated, "From the outset, we denied and we continue to strongly deny the allegations asserted against us in the underlying litigation. Given Avenir's agreement to reimburse us for the attorneys' fees we incurred in defending against those allegations, included in the new note, and its acknowledgement that Ionic complied in all material respects with the controlling agreements relating to the 2020 financing, we concluded that it made good business sense to bring the dispute to a close."
Overall, Avenir Wellness Solutions has never been in a better position to capitalize on the high intrinsic value of our Nutri-Strip products as well as our unique and proprietary skin care formulations. With 17 patents under our control, the highly positive reviews Seratopical Revolution DNA Complex is receiving, and more new products in development, 2025 is setting up to be a growth year for the Company. We look forward to keeping our shareholders informed of our progress, developments and milestones as we move forward.
Company Management will be hosting an investor webcast/call to discuss the settlement agreement and provide an update on the Company on Wednesday, December 18, 2024 at 1:00pm PST / 4:00pm EST. Questions may be submitted prior to the webcast by emailing them to investor@avenirwellness.com. To participate in the webcast, please join us at:
https://us06web.zoom.us/j/83688826398?pwd=NzGBQ928B7m34yGgLPBPLI77BY4lGF.1
Meeting ID: 836 8882 6398
Passcode: 797030
One tap mobile
+16694449171,,83688826398#,,,,*797030# US
+13462487799,,83688826398#,,,,*797030# US (Houston)
About Avenir Wellness Solutions, Inc.
Avenir Wellness (OTCQB: AVRW) is a broad platform technology company that develops proprietary wellness, nutraceutical, and topical delivery systems. The technology, which is based on fifteen current patents, offers a number of unique immediate- and controlled-release delivery vehicles designed to improve product efficacy, safety, and consumer experience for a wide range of active ingredients. The Company will continue down the path of creating new technologies that is part of its incubator strategy in order to monetize its intellectual property by expanding its product lines utilizing the technology. And, as a vertically integrated platform company, Avenir also looks to partner with or license its IP technology to wellness companies worldwide. For more information visit: www.avenirwellness.com.
About The Sera Labs, Inc.
The Sera Labs, Inc. ("Sera Labs"), a wholly owned subsidiary of Avenir, is a trusted leader in the health, wellness, and beauty sectors with innovative products using cutting-edge technology. Sera Labs creates high-quality products that use science-backed, proprietary formulations. More than 25 products are sold under the brand names Seratopical™, Seratopical Revolution™, SeraLabs™, and Nutri-Strips™. Sera Labs sells its products at affordable prices, making them easily accessible on a global scale. Strategically positioned in the growth market categories beauty, health & wellness, Sera Labs products are sold direct-to-consumer (DTC) via online website orders, including opt-in subscriptions, and also sold online and in-store at major national drug, grocery chains, convenience stores, and mass retailers and on Amazon.com. For more information visit: www.seralabshealth.com and follow Sera Labs on Facebook and Instagram at @seratopical, as well as on X (Twitter) at @sera_ labs.
Forward Looking Statement
This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, which statements are subject to considerable risks and uncertainties. Forward-looking statements include all statements other than statements of historical fact contained in this press release, including statements regarding the future growth and success of our organization. We have attempted to identify forward-looking statements by using words such as "anticipate," "believe," "could," "estimate," "expected," "intend," "may," "plan," "predict," "project," "should," "will," or "would," and similar expressions or the negative of these expressions.
Forward-looking statements represent our management's current expectations and predictions about trends affecting our business and industry and are based on information available as of the time such statements are made. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy or completeness. Forward-looking statements involve numerous known and unknown risks, uncertainties and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements predicted, assumed or implied by the forward-looking statements. Some of the risks and uncertainties that may cause our actual results to materially differ from those expressed or implied by these forward-looking statements are described in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as well as in our Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. Except as required by applicable law, we expressly disclaim any intent or obligation to update any forward-looking statements, or to update the reasons actual results could differ materially from those expressed or implied by these forward-looking statements, whether to conform such statements to actual results or changes in our expectations, or as a result of the availability of new information.
Contacts:
Investor Relations
Hanover International Inc.
E: investor@avenirwellness.com
T: (760) 564-7400
SOURCE: Avenir Wellness Solutions, Inc.
Looks like a DEAD 10Q Bounce.
Kind of looks like some gambler's came in on basic technicals and didn't
read deeply into the report. Had a small bounce and now is trailing back
off again. I expect to see new lows soon.
BANKRUPTCY or MIRACLE - that is the question.
More buying volume for AVRW on this half trading day which just closed. The accumulation and uptrend are becoming more clear.
Avenir Wellness Solutions Inc (OTCQB: AVRW)
0.04495 +0.00055 (+1.24%)
Volume: 121,175
Day Range: 0.04235 - 0.05
Last Trade Time: 11:50:21 AM EST
Holders should take 3 cents before the bankruptcy.
Not sure why PS keeps posting nonsense.
Have a great weekend SOTG !
BANKRUPTCY has to be coming here soon.
Another good day for AVRW with more buying volume and trades as high as .0575 to continue the current uptrend.
Avenir Wellness Solutions Inc (OTCQB: AVRW)
Last: 0.0499 0.00 (0.00%)
Volume: 48,155
Day Range: 0.031 - 0.0575
Last Trade Time: 2:11:04 PM EST
Either a Gambler - or - Delusional - BANKRUPTCY
Looms.
They definitely didn't read that horrendous 10Q or
they don't know how to read a 10Q.
Nice close for AVRW today with another gain to continue the recent uptrend. Investors are seeing that there is good upside potential here as the company continues to develop its business plans. It's also very positive that management is keeping all required SEC filings up to date to maintain their valuable OTCQB listing status.
Avenir Wellness Solutions Inc (OTCQB: AVRW)
Last: 0.0499 +0.00495 (+11.01%)
Volume: 3,423
Day Range: 0.0499 - 0.0499
Last Trade Time: 3:53:25 PM EST
No kidding. BANKRUPTCY ????
I need to dig a little further in the transactions section as I read that they had
received the remainder of the $2MM from good ole RD (somehow someway)
but I have not spotted those particular payments in the spreadsheet data.
Anyhow - Sales have indeed dropped sharply, they are sharing space in the
distribution center and have no main offices any longer, and yes indeed - the
debt just keeps piling up and the interest rates are killing them too.
Sad sad sad. Oh... and is RD still Chairman of the Board ??
As of September 30, 2024, the Company had $11 thousand of cash on hand, had an accumulated deficit of $126.1 million and a working capital deficit of $13.1 million. Our operating activities consume a portion of our cash resources. We anticipate that we will continue to incur operating losses and negative cash flows from operations as we execute our strategic and business development initiatives. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The Company may need to complete additional equity or debt financings to fully execute its business plans and strategies.
NEW LOWS ARE COMING SOON......
After reading that 10Q, my guess is there will be a lot of selling tomorrow.
THEY HAVE NO OFFICIAL OFFICES ANY LONGER.....
Operating Lease
The Company currently maintains its corporate offices at 15233 Ventura Boulevard, Suite 420, Sherman Oaks, CA 91403 at no cost to the Company under an informal arrangement with its tenant while the Company seeks to identify suitable permanent office space. The Company previously maintained its leased corporate offices at 5805 Sepulveda Boulevard, Suite 500, Sherman Oaks, CA 91411 under a lease agreement (the “Lease”), which was originally set to expire on April 30, 2026. Effective on September 6, 2024, the Company early terminated the lease without penalty by mutual agreement with the landlord and the Company vacated the premises. The lease provided for the payment of base monthly rent in the amount of $7 thousand during the first 12 months of the term with an increase of 3% over the base monthly rent beginning on the one-year anniversary of the Lease. The Company previously occupied Suite 801 in the same building under a lease agreement that expired on April 30, 2024.
Horrendous 10Q - THE TOILET IS FLUSHING
Read it all closely - they have less cash on hand than current liabilities.
So, they are more than broke !! Sales are absolutely horrible.
https://www.sec.gov/ix?doc=/Archives/edgar/data/1643301/000147793224007414/avrw_10q.htm
BANKRUPTCY is a long and slow bleed here - Miracle coming? Doesn't appear so.
Fingers crossed that the future shows increased sales. Filing is always good news.
AVRW has filed the company's 3rd quarter financial results today, well within the normal extension time frame for its due date of November 15th. Management is keeping the company is good standing and is now fully up to date again with this filing. As the company makes more progress on its developing business plans there is a lot of upside stock price appreciation potential here from the current base support pps levels.
Avenir Wellness Solutions, Inc. (Form: 10-Q, Received: 11/19/2024 13:34:16)
Link:
https://www.otcmarkets.com/filing/html?id=17986389&guid=cmY-kpB8kdwfJth
BETS ON ANOTHER DELISTING TO PINKS?????
It's only been about a year ago that they were moved to the Pinks
after not filing on time.
Anyhow, I think it might be prudent to consider the fact that this time off
they are probably even more strapped for cash than last time.
As a direct result of the timing of the change in Avenir's auditor, the completion of its 2022 annual audit and the filing of its Form 10-K were delayed beyond the May 15, 2023 OTC Markets Group's deadline and, effective as of May 17, 2023, Avenir's common stock was moved from the OTCQB to the OTC Pink Market. Upon getting current with its SEC filings, the Company immediately re-applied to move the trading of its securities back to the OTCQB. On September 14, 2023, the OTC Markets Group notified the Company that its common stock would be re-listed on the OTCQB, effective September 15, 2023.
LATE FILING NOTICE ONCE AGAIN......
FORM 12b-25 for NT-10Q Late filing
No big surprise here - they are late more times than they are on time.
Still calling BANKRUPTCY on this one without a MIRACLE.
Nice close at the .05 level today for AVRW. The uptrend continues here.
AVRW Avenir Wellness Solutions Inc (OTC: AVRW)
Last: 0.05 +0.015425 (+44.61%)
Volume: 59,939
Day Range: 0.04 - 0.05
Last Trade Time: 3:30:47 PM EST
Good week for AVRW with the uptrend continuing and substantial bud support solidifying now. Looking forward to the company's Q3 financial filing due next week and hopefully some new press announcements on their progress and plans going forward.
We are going to need some good news here. Companies can be more resilient than hey appear to be. Hoping we get some good news here and they can turn this around. Tough running a company when one is counting pennies. I personally have done that before. Looking for a decent Q3 to start the rise. Let's see.
AVRW is due to report Q3 numbers this month by November 15th. Management is very reliable about keeping all its filings up to date so the stock remains in good standing for its OTC listing. We will likely see the upcoming filing on time and hopefully some fresh news on progress and the latest developments. Lots of potential for pps rise here from current base trading levels.
Agreed, I've been warning here for several years.
Not a lot of time to respond. But, if we are on the same page,
I posted some time ago about Avenir/Sera Labs having downsized
from the 8th floor down to the 5th in the building they lease at. I think
this is what you refer to - but not sure. They are in the same building
but now on the 5th floor.
The transparency here is indeed like a window painted over black.
Bankruptcy or Miracle - I still say bankruptcy looks inevitable.
New ALL TIME LOW, drops below 2 cents
$AVRW continues down down down
Sounds like something done to the pavement 🤣
$AVRW is going down down down.
This Product Celebrity Endorsed And 300% less money......
https://www.yahoo.com/lifestyle/olivia-wilde-40-loves-cerave-and-its-bestselling-eye-cream-is-on-sale-for-just-14-125055766.html
So why buy something Nicole Kidman says is great when Olivia Wilde says this is great for 3 X less cash out of your bank account...... ??
(I am comparing equal amounts in volume 2 each of the Cerave @ .5 oz compared to 1 each Seratopical DNA at 1oz.)
$AVRW - will they drop below 2 cents next week ????
$AVRW - will they go BANKRUPT or will a MIRACLE occur ????
Watch Nicole Kidman’s video for $AVRW on Instagram here:
https://www.instagram.com/reel/CyGgu2pr8zA/?
Just look at 2.2/5 Better Business Bureau numbers
Well SOTG & WF11, We have presented facts and numbers related
to 8K's, 10Q's and 10K's as well as pointed out some of the information
related to past products, manager's and the musical chair name game.
The BBB is generally a decent indicator of what people think about the
company. Their BBB score is 2.2 out of 5 ratings. It's a mixed bag of
comments both good and bad - but overall - it's bad.
Besides having no money - they have an awful reputation on customer
service, monthly recurring charges without efficient reviews etc. etc. etc.
Current price 2 cents
Current bid .0106 10K shares
Current ask .0298 10K shares
https://www.bbb.org/us/ca/sherman-oaks/profile/health-and-wellness/the-sera-labs-inc-1216-1084307/customer-reviews
The AVRW Sera Labs product line has never been more appealing and effective. Everyone can see it here and place orders too:
https://seralabshealth.com/
|
Followers
|
35
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3852
|
|
Created
|
11/14/16
|
Type
|
Free
|
| Moderators ProfitScout Dickmo Student of the Game | |||
Avenir Wellness Solutions (OTC: AVRW)
Formerly CURE Pharmaceutical (OTC: CURR)
For more information, please visit: www.avenirwellness.com and www.seralabshealth.com
COMPANY UPDATE:
Press Release | 02/13/2024
Link: https://feeds.issuerdirect.com/news-release.html?newsid=6554360501139897
Brand New Avenir Wellness DNA Product: https://seralabshealth.com/products/dna-complex
CEO INTERVIEW on Apple Podcasts:
"Lifetime of Health and Wellness - Nancy Duitch, CEO The Sera Labs"
Host April Franzino is joined by:
Nancy Duitch, CEO of The Sera Labs (see image below).
"Nancy discusses how she has spent her entire career working on solution-based health, wellness and beauty products to help people look and feel their absolute best."
Instagram: https://www.instagram.com/beautybizshow/
See omnystudio.com/listener for privacy information.
AVENIR WELLNESS: BUILDING INOVATIVE WELLNESS TECHNOLOGIES FOR THE FUTURE
Avenir Wellness is a vertically integrated drug delivery and development company
Committed to improving drug efficacy, safety, and patient experience through its proprietary drug dosage
Spokesperson Nicole Kidman, Actor (see image below).
Visit the Seratopical Store on AMAZON
LINK: https://www.amazon.com/stores/SERATOPICAL/page/473637CB-F4D4-470C-B60D-7B3885CDED6E?ref_=ast_bln
The plant based, alcohol-free, non-CBD, anti-aging beauty line is available Wednesday, June 9
Sera Labs, a subsidiary of Avenir Wellness Solutions, announced a new ad campaign and launch of Seratopical Revolution, a new clean, plant-based, technologically advanced, anti-aging, ‘revolutionary,’ beauty line.
Nicole Kidman and Sera Labs Inc., an Avenir Wellness Solutions Company, launch Seratopical Revolution. (Photo: Business Wire)
The line touts 11 luxurious products which are all are made in the U.S., available at accessible pricing, and are designed to make you feel more youthful and hydrated from head to toe. Award-winning actress Nicole Kidman, Sera Labs’ strategic business partner and global brand ambassador, collaborated with Sera Labs to design the Loving Hands Essential Oil , Indulgence Brown Sugar Scrub , Harmony Face & Neck Toner , and Gleaming for the ultimate brightening glow. The full line of products can be seen at Seratopicalrevolution.com .
“I really wanted to create something that was meaningful to me and that I knew people would genuinely enjoy,” said Kidman, Seratopical strategic business partner and global brand ambassador. “These products are personal to me from the scent to the texture. I am so excited to share them with the world and hope everyone loves them as much as we do.”
Seratopical Revolution marries nature and science into one clean and nourishing line of beauty products. The line’s P?P complex, developed by CURE Pharmaceutical, drives natural, plant-based ingredients into the deeper layers of the skin by utilizing a proprietary tri-peptide delivery system. Unlike other companies that use alcohol as a delivery system, which is incredibly drying to the skin, Seratopical Revolution’s natural oil and surfactant delivery systems are efficacious and offer almost immediate results.
“It’s been an incredible ride creating this line with Nicole,” said Nancy Duitch , Sera Labs CEO and CURE Pharmaceutical Chief Strategic Officer. “There are a lot of beauty companies, but the problem is that most of them don’t understand that without an effective delivery system, the products are sitting on top of your skin and clogging your pores. Our proprietary formulators have developed a high-tech delivery system which allows the ingredients to go deep into the skin. Our loyal customers will benefit from scientifically backed ingredients that are designed to enhance hydration and rejuvenate collagen. Revolution offers a full-body line packed with natural plant extracts and peptide blends.”
Seratopical Revolution products can be purchased online at seratopicalrevolution.com
Ad campaign photo and product images: https://www.dropbox.com/sh/o8l39o5xb0yj4bs/AAAj1WTWRwK05EpziP4BJn7ka?dl=0
For more information visit: Seratopical.com , Seralabshealth.com and follow us on Instagram at @seratopical , as well as Twitter , and Facebook . Media contact: press@theseralabs.com .
About Sera Labs
Sera Labs® is a trusted leader in the health, wellness, and beauty sectors of innovative products with cutting edge technology and superior ingredients such as CBD and clean plant-based products. Sera Labs creates high quality products that use science-backed, proprietary formulations. Its more than 20 products are sold under the brand names Seratopical ™, SeraLabs™, and Gordon’s Herbals™. Sera Labs sells its products at affordable prices, making them easily accessible on a global scale. Strategically positioned in the growth market categories of beauty, health & wellness. Sera Labs products are sold in major national drug, grocery chains and mass retailers. The company also sells products under private label to major retailers and multi-level marketers, as well as direct-to-consumer (DTC), via online website orders, including opt-in subscriptions. For more information visit: Seratopical.com , Seralabshealth.com and follow us on Instagram at @seratopical , as well as Twitter , and Facebook . Media contact: press@theseralabs.com .
About Avenir Wellness Solutions Company
Avenir Wellness is the pioneering developer of CUREform™, a patented drug delivery platform that offers a number of unique immediate- and controlled-release drug delivery vehicles designed to improve drug efficacy, safety, and patient experience for a wide range of active ingredients. As a vertically integrated company, AVRW’s 25,000 square foot, FDA-registered, NSF® cGMP-certified manufacturing facility enables it to partner with pharmaceutical and wellness companies worldwide for private and white-labeled production. Avenir has partnerships in the U.S., China, Mexico, Canada, Israel, and other markets in Europe.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210609005442/en/
Avenir Wellness [OTC: AVRW] and Canopy Growth to Produce CBD Oral Thin Films
AVRW has an FDA- and DEA- registered, GMP manufacturing facility and is a pioneering developer of CUREform™, a patented drug delivery platform. CUREform™ includes CUREfilm®, one of the most advanced oral thin films on the market today; microCURE™, an innovative emulsion technology utilizing proprietary encapsulation techniques; and CUREpods™ a novel chewable delivery system.
AVRW names Canopy Rivers Chairman John K. Bell, FCA, FCPA, ICD.D to its board of directors. Bell brings more than 40 years of experience to the company, most recently serving as chairman of the Canopy Rivers board of directors and former chairman of Canopy Growth’s board of directors.
AVRW offers combined technologies that provide opportunities for both immediate and controlled-release drug delivery of a wide range of active ingredients. AVRW partners with biotech, pharmaceutical, and wellness companies worldwide and has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector, with partnerships in the U.S.A, Canada, Israel, and other markets. The AVRW company mission is to improve people’s lives by redefining how medicines are delivered and experienced.
AVRW Products Fall Into Two Categories: Nutraceuticals (dietary supplements) and Pharmaceutical Medicines
Nutraceuticals:
CUREfilm® Sleep is a daily dietary supplement that delivers a unique blend of five active ingredients with the CUREfilm® platform to promote healthy sleep patterns. This product is launched in U.S. markets.
CUREfilm® D is a high-potency dietary supplement that provides 50,000 IU of Vitamin D3 delivered with the CUREfilm® platform.
CUREfilm™ Hemp delivers hemp extracts via the CUREfilm® dosage form. This product is launched in U.S. markets.
CUREfilm® β-Caryophyllene is a dietary supplement that contains 30mg of β-Caryophyllene, a powerful terpene known for its anti-inflammatory and analgesic properties.
Pharmaceuticals:
CUREfilm® Blue contains 50mg of Sildenafil delivered with the CUREfilm® platform.
CUREfilm® Canna delivers synthetic and plant-derived cannabinoids in an oral thin film for pharmaceutical indications.
AVRW Expands to Europe, Signs Licensing Agreement with ReLeaf Europe to Provide Advanced Cannabinoid Delivery
On February 5th AVRW announced that it had signed an exclusive licensing agreement with ReLeaf Europe, one of Europe’s leading pharmaceutical groups specialized in medicinal cannabis products. The agreement grants ReLeaf Europe exclusive access to the AVRW encapsulation technology for certain oral and topical cannabis products in the Netherlands, the world’s first medical cannabis market. ReLeaf Europe products will be the first to use the CUREinside™ quality mark to bolster consumer confidence. Europe is one of the world’s largest medical cannabis markets due to various governments’ approval for medicinal purposes.
ReLeaf Europe is one of the few pharmacy providers of pharmaceutical-grade medicinal cannabis oils in Europe and an ideal partner for the AVRW first step into the European market because of its commitment to establishing clinical evidence and following EU GMP and GDP standards. Through this agreement, AVRW will roll out its powered by CURE strategy that includes exclusive licensing relationships to build global market share.
ReLeaf Europe is tackling the largest market in the world for cannabis by establishing a foothold in Holland — a market estimated to reach $2.6B by 2028 — and by pursuing innovative delivery systems and distribution networks. AVRW will power several ReLeaf Europe products, including one sublingual tincture and two topical creams to be launched in 2020.
Major Earnings Potential in the Emerging Medicinal Cannabis Industry
The Cannabis plant has an estimated 113 different compounds, out of which THC and CBD are the two main constituents. THC is mainly responsible for the psychoactive effects or the
feeling of “high” caused by the use of cannabis. CBD on the other hand, has several powerful anti-inflammatory, analgesic, neuroprotective and anti-anxiety properties, which explains its growing popularity to treat a plethora of medical conditions. Unlike THC, CBD does not have any psychotropic effects and hence is widely preferred.
CBD is now being used to treat a wide array of medical conditions such as cancer, cardiovascular anomalies, arthritis, anxiety, depression and Insomnia. In addition, it has also been proven to possess neuroprotective benefits that can treat diseases such as seizures, Multiple Sclerosis (MS), Alzheimer’s, Parkinson’s and Schizophrenia to name a few. There is a growing preference for CBD over traditional pharmaceutical options as these have minimal side effects and are non-addictive.
The global legal marijuana market is likely to reach over USD 66.3 billion by the end of 2025, as per a report by Grand View Research, Inc, growing at a CAGR of 23.9%. There is a growing acceptance of the curative effects of cannabis, with some countries such as Canada and certain states of U.S legalizing the use of Marijuana for medical and recreational use. Research has time and again shown that cannabinoids (CBD), extracted from the cannabis plant, have varied medical uses with minimal side effects, making it a sought-after alternative to traditional pharmaceutical options.
AVRW has signed a licensing and collaboration agreement with
Vanguard Scientific Systems, Inc.
Vanguard is a premier provider of equipment, systems and performance solutions servicing the botanical extraction industry, including the MIDAS XII, a next-generation GMP compliant supercritical CO2 extraction technology, as well as industrially scaled CO2 facility solutions. The license gives Vanguard the right to practice CURE’s patented cannabis extraction methods, providing customer confidence in choosing Vanguard’s portfolio of extraction manufacturers
The industry is poised to grow to $2.1 billion in 2020, a 700% increase from 2016. Those numbers are not only appealing to the players in the CBD market but also serve as an incredible opportunity the pharmaceutical companies to create novel solutions for disease with large unmet medical needs. AVRW is strategically positioned with multiple high value assets and extremely well-placed marketing partners to optimize the company’s earnings potential in the growing fields of key drug supply and delivery solutions, including the multi-billion-dollar CBD marketplace. For more information on Avenir Wellness (OTCQB: AVRW ) visit: http://www.avenirwellness.com
Company News
02/13/2024 Avenir Wellness Solutions Issues 2024 Marketing Growth Plans to Shareholders for Seratopical Revolution Skin Care Line with Support from Nicole Kidman and
Facial Plastic Surgeon Dr. Michael Persky
09/19/2023 Avenir Wellness Solutions Announces Return of Stock Trading Back to OTCQB Market
08/08/2023 Avenir Wellness Solutions Announces New Ticker Symbol As Final Part of Exciting New Brand Identity
05/17/2023 Avenir Wellness Solutions Update to Stockholders
04/28/2023 New to The Street Announces the Televised Lineups for Shows 461, 462, and 463; Airings on Three Networks Will Begin on Saturday, April 29, 2023, at 3:30 PM ET
04/26/2023 Avenir Wellness Solutions (OTCQB:CURR) to Present at the Planet MicroCap Showcase - Live Webcast Available
04/25/2023 Avenir Wellness Letter to Stockholders
04/13/2023 New to The Street Announces the Televised Lineups for Shows 452, 457, and 458, Airings on Three Networks Will Begin Tonight, Thursday, April 13, 2023, at 9:30 PM ET
DISCLAIMER:
Nothing in the contents transmitted on this board should be construed as an investment advisory, nor should it be used to make investment decisions. There is no express or implied solicitation to buy or sell securities. The author(s) may have positions in the stocks or financial relationships with the company or companies discussed and may trade in the stocks mentioned. Readers are advised to conduct their own due diligence prior to considering buying or selling any stock. All information should be considered for information purposes only. No stock exchange has approved or disapproved of the information here.
AI
